Some Advances in Malaria Control in Nigeria:

Abstract

Malaria remains a significant public health challenge in Nigeria, contributing to high morbidity and mortality, especially among vulnerable groups such as children under five and pregnant women. This review examines some advances in malaria control in Nigeria, focusing on prevention, diagnosis, and treatment strategies. Interventions such as insecticide-treated nets (ITNs), artemisinin-based combination therapies (ACTs), rapid diagnostic tests (RDTs), and the recombinant protein-based malaria vaccine subtype (RTS,S) have collectively reduced malaria prevalence and improved health outcomes. Targeted mass distribution campaigns for ITNs and the adoption of ACTs as the first-line treatment have significantly curtailed malaria transmission and child mortality rates by 20%. Advances in diagnostic technologies, including RDTs, have enhanced accurate and timely case management. The introduction of the RTS, vaccine in high-burden regions marks a critical milestone in protecting vulnerable populations. In Nigeria, the vaccine rollout has been strategically targeted to selected states with the highest malaria transmission rates. As part of the national implementation strategy, the phased deployment of the RTS,S vaccine began in 2024, with Nasarawa, Kwara, and Ondo identified as the initial pilot states. These areas were chosen based on their malaria burden, health system readiness, and commitment to disease control efforts. Additionally, innovations in vector control, integrated strategies combining multiple interventions, and community engagement have strengthened malaria control efforts in Nigeria.